Addex Therapeutics (ADXN) Change in Account Payables (2019 - 2025)

Addex Therapeutics has disclosed Change in Account Payables across 7 years of filings, most recently posting -$185.3 billion for Q2 2025.

• Change in Account Payables for Q2 2025 came in at -$185.3 billion, up 82.01% year-over-year; the trailing twelve-month figure through Jun 2025 was -$28.1 billion (down 104.18% YoY), and the FY2025 annual result was $471878.5, up 136.07% from the prior year.
• Change in Account Payables came in at -$185.3 billion for Q2 2025 at Addex Therapeutics, down from $170.6 billion in the prior quarter.
• In the past five years, Change in Account Payables ranged from a high of $1411.3 billion in Q4 2023 to a low of -$1224.9 billion in Q3 2024.
• The 5-year median for Change in Account Payables is -$154425.5 (2022), against an average of $796.0 million.
• Across the five-year window, Change in Account Payables tumbled 246610803.76% in 2023 and soared 18946372486.98% in 2024, its largest moves.
• Addex Therapeutics' Change in Account Payables stood at $476259.1 in 2021, then plunged by 272.42% to -$821184.3 in 2022, then surged by 171865410.82% to $1411.3 billion in 2023, then decreased by 14.16% to $1211.5 billion in 2024, then plunged by 115.29% to -$185.3 billion in 2025.
• The last three Change in Account Payables figures came in at -$185.3 billion (Q2 2025), $170.6 billion (Q1 2025), and $1211.5 billion (Q4 2024), per Business Quant data.